Floatz logo

Thalidomide

Brain and Central Nervous System Tumors

Medical University of ViennaSmall moleculePhase 2Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Brain and Central Nervous System Tumors cohort.

Asset / SponsorPhaseRating
Procarbazine
Universitätsmedizin Mannheim
Phase 3BBB
VINCRISTINE SULFATE
Northwestern University
Phase 3BBB
Irinotecan
EpicentRx, Inc.
Phase 2BBB
Gefetinib
Memorial Sloan Kettering Cancer Center
Phase 2BBB
ETOPOSIDE
NewLink Genetics Corporation
Phase 3BBB

View all 50 →

Same molecule, other indications

Thalidomide is also rated in:

uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
beta-thalassemia majorDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →